Yibai Pharmaceutical announced that the Guizhou Medical Products Administration intends to fine it 700,000 yuan for failing to comply with Good Manufacturing Practice for Drugs during the production of children's cough syrup. The penalty stems from inspections that uncovered issues such as non-standard excipient testing and inconsistent disinfection records. The company had its production and sale of this drug suspended in August 2025, resuming in September after rectification. Earlier, in April 2024, its core product Aidi injection was fined over 8.2 million yuan and had production halted for similar violations, and it has yet to resume production. Financial data shows that in 2024, 2025, and the first half of 2026, the company's net profit attributable to shareholders was negative 317 million yuan, negative 330 million yuan, and an estimated loss of 74 million to 88.8 million yuan, respectively, with cumulative losses exceeding 700 million yuan over two and a half years. Meanwhile, the company's research and development expenses declined for five consecutive years, from 136 million yuan in 2021 to 84 million yuan in 2025.
Guizhou Yibai Pharmaceutical Co LtdFined 700,000 yuan for GMP violations in children's cough syrup production, with prior fines and suspensions.
